Patents by Inventor Glenn E. Dale
Glenn E. Dale has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11903934Abstract: The invention provides formulations containing highly concentrated solutions of rifabutin and methods of making such formulations. The invention also provides methods of using such formulations to treat a bacterial infection in a subject.Type: GrantFiled: May 27, 2022Date of Patent: February 20, 2024Assignee: BIOVERSYS AGInventors: Glenn E. Dale, Sergio Lociuro, Marc Gitzinger, Stefano Biondi, Marilyne Bourotte
-
Publication number: 20240041845Abstract: The invention provides systems and methods for increased clinical efficacy of rifabutin against A. baumannii. The invention takes advantage of the discovery of a ferric-coprogen (FhuE) receptor that is responsible for the uptake of rifabutin into A. baumannii cells. Methods preferably include obtaining a sample from a patient suspected of having an infection; performing a test on the sample to identify an infection of A. baumannii in the patient; and providing a formulation of rifabutin for treating the patient that, when administered to the patient, maximizes a resultant AUC and/or Cmax. The method may include administering the formulation of rifabutin to the patient. Preferably the formulation is delivered to the patient, e.g., by intravenous injection and results in a Cmax is that greater than about 2 mg/L and optionally less than about 50 mg/L.Type: ApplicationFiled: October 20, 2023Publication date: February 8, 2024Inventors: Glenn E. Dale, Sergio Lociuro, Christian Kemmer, Vincent Trebosc, Marc Gitzinger
-
Publication number: 20240000759Abstract: The invention provides antibiotic combination therapies for treating an A. baumannii infection in a subject. The combination therapies include rifabutin and a second antibiotic, such as colistin and cefiderocol.Type: ApplicationFiled: September 12, 2023Publication date: January 4, 2024Inventors: Vincent Trebosc, Christian Kemmer, Glenn E. Dale, Sergio Lociuro, Marc Gitzinger
-
Patent number: 11833139Abstract: The invention provides systems and methods for increased clinical efficacy of rifabutin against A. baumannii. The invention takes advantage of the discovery of a ferric-coprogen (FhuE) receptor that is responsible for the uptake of rifabutin into A. baumannii cells. Methods preferably include obtaining a sample from a patient suspected of having an infection; performing a test on the sample to identify an infection of A. baumannii in the patient; and providing a formulation of rifabutin for treating the patient that, when administered to the patient, maximizes a resultant AUC and/or Cmax. The method may include administering the formulation of rifabutin to the patient. Preferably the formulation is delivered to the patient, e.g., by intravenous injection and results in a Cmax is that greater than about 2 mg/L and optionally less than about 50 mg/L.Type: GrantFiled: June 6, 2022Date of Patent: December 5, 2023Assignee: BIOVERSYS AGInventors: Glenn E. Dale, Sergio Lociuro, Christian Kemmer, Vincent Trebosc, Marc Gitzinger
-
Publication number: 20230364065Abstract: The invention provides antibiotic combination therapies for treating an A. baumannii infection in a subject. The combination therapies include rifabutin and a member of the polymyxin class of antibiotics, such as commercially available natural products antibiotics, e.g., polymyxins B and polymyxins E (colistin and its pro-drug colistin methane sulfonate (CMS)) and synthetic or semi-synthetic derivatives and analogs, e.g., SPR206, MRX-8 and QPX9003 and polymyxin-like antibiotics, e.g.Type: ApplicationFiled: November 1, 2022Publication date: November 16, 2023Inventors: Sergio Lociuro, Glenn E. Dale, Marc Gitzinger, Vincent Trebosc
-
Patent number: 11766425Abstract: The invention provides antibiotic combination therapies for treating an A. baumannii infection in a subject. The combination therapies include rifabutin and a second antibiotic, such as colistin and cefiderocol.Type: GrantFiled: December 27, 2021Date of Patent: September 26, 2023Inventors: Vincent Trebosc, Christian Kemmer, Glenn E. Dale, Sergio Lociuro, Marc Gitzinger
-
Publication number: 20230132691Abstract: The invention provides systems and methods for increased clinical efficacy of rifabutin against A. baumannii. The invention takes advantage of the discovery of a ferric-coprogen (FhuE) receptor that is responsible for the uptake of rifabutin into A. baumannii cells. Methods preferably include obtaining a sample from a patient suspected of having an infection; performing a test on the sample to identify an infection of A. baumannii in the patient; and providing a formulation of rifabutin for treating the patient that, when administered to the patient, maximizes a resultant AUC and/or Cmax. The method may include administering the formulation of rifabutin to the patient. Preferably the formulation is delivered to the patient, e.g., by intravenous injection and results in a Cmax is that greater than about 2 mg/L and optionally less than about 50 mg/L.Type: ApplicationFiled: June 6, 2022Publication date: May 4, 2023Inventors: Glenn E. Dale, Sergio Lociuro, Christian Kemmer, Vincent Trebosc, Marc Gitzinger
-
Patent number: 11629171Abstract: Beta-hairpin peptidomimetics of the general formula (I), and pharmaceutically acceptable salts thereof, with P, X, Q., and optionally L being elements as defined in the description and the claims, have Gram-negative antimicrobial activity to e.g. inhibit the growth or to kill microorganisms such as Klebsiella pneumoniae and/or Acinetobacter baumannii and/or Escherichia coli and/or Pseudomonas aeruginosa and/or Enterobacter cloacae. They can be used as medicaments to treat or prevent infections or as disinfectants for foodstuffs, cosmetics, medicaments or other nutrient-containing materials. These peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.Type: GrantFiled: November 12, 2018Date of Patent: April 18, 2023Assignee: Spexis AGInventors: Daniel Obrecht, Anatol Luther, Francesca Bernardini, Glenn E. Dale, Nicolas Desjonqueres, Emile Brabet, Grégory Upert
-
Publication number: 20230066182Abstract: The invention provides formulations containing highly concentrated solutions of rifabutin and methods of making such formulations. The invention also provides methods of using such formulations to treat a bacterial infection in a subject.Type: ApplicationFiled: May 27, 2022Publication date: March 2, 2023Inventors: Glenn E. Dale, Sergio Lociuro, Marc Gitzinger, Stefano Biondi, Marilyne Bourotte
-
Publication number: 20220184048Abstract: The invention provides antibiotic combination therapies for treating an A. baumannii infection in a subject. The combination therapies include rifabutin and a second antibiotic, such as colistin and cefiderocol.Type: ApplicationFiled: December 27, 2021Publication date: June 16, 2022Inventors: Vincent Trebosc, Christian Kemmer, Glenn E. Dale, Sergio Lociuro, Marc Gitzinger
-
Patent number: 11351158Abstract: The invention provides systems and methods for increased clinical efficacy of rifabutin against A. baumannii. The invention takes advantage of the discovery of a ferric-coprogen (FhuE) receptor that is responsible for the uptake of rifabutin into A. baumannii cells. Methods preferably include obtaining a sample from a patient suspected of having an infection; performing a test on the sample to identify an infection of A. baumannii in the patient; and providing a formulation of rifabutin for treating the patient that, when administered to the patient, maximizes a resultant AUC and/or Cmax. The method may include administering the formulation of rifabutin to the patient. Preferably the formulation is delivered to the patient, e.g., by intravenous injection and results in a Cmax is that greater than about 2 mg/L and optionally less than about 50 mg/L.Type: GrantFiled: August 3, 2020Date of Patent: June 7, 2022Assignee: BIOVERSYS AGInventors: Glenn E. Dale, Sergio Lociuro, Christian Kemmer, Vincent Trebosc, Marc Gitzinger
-
Patent number: 11344537Abstract: The invention provides formulations containing highly concentrated solutions of rifabutin and methods of making such formulations. The invention also provides methods of using such formulations to treat a bacterial infection in a subject.Type: GrantFiled: August 3, 2020Date of Patent: May 31, 2022Assignee: BIOVERSYS AGInventors: Sergio Lociuro, Stefano Biondi, Glenn E. Dale, Marilyne Bourotte, Marc Gitzinger
-
Patent number: 11207305Abstract: The invention provides antibiotic combination therapies for treating an A. baumannii infection in a subject. The combination therapies include rifabutin and a second antibiotic, such as colistin and cefiderocol.Type: GrantFiled: August 3, 2020Date of Patent: December 28, 2021Assignee: BIOVERSYS AGInventors: Vincent Trebosc, Christian Kemmer, Glenn E. Dale, Sergio Lociuro, Marc Gitzinger
-
Publication number: 20210284693Abstract: Beta-hairpin peptidomimetics of the general formula (I), and pharmaceutically acceptable salts thereof, with P, X, Q., and optionally L being elements as defined in the description and the claims, have Gram-negative antimicrobial activity to e.g. inhibit the growth or to kill microorganisms such as Klebsiella pneumoniae and/or Acinetobacterbaumannii and/or Escherichia coli and/or Pseudomonas aeruginosa and/or Enterobacter cloacae. They can be used as medicaments to treat or prevent infections or as disinfectants for foodstuffs, cosmetics, medicaments or other nutrient-containing materials. These peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.Type: ApplicationFiled: November 12, 2018Publication date: September 16, 2021Inventors: Daniel OBRECHT, Anatol LUTHER, Francesca BERNARDINI, Glenn E. DALE, Nicolas DESJONQUERES, Emile BRABET, Grégory UPERT
-
Publication number: 20210077471Abstract: The invention provides systems and methods for increased clinical efficacy of rifabutin against A. baumannii. The invention takes advantage of the discovery of a ferric-coprogen (FhuE) receptor that is responsible for the uptake of rifabutin into A. baumannii cells. Methods preferably include obtaining a sample from a patient suspected of having an infection; performing a test on the sample to identify an infection of A. baumannii in the patient; and providing a formulation of rifabutin for treating the patient that, when administered to the patient, maximizes a resultant AUC and/or Cmax. The method may include administering the formulation of rifabutin to the patient. Preferably the formulation is delivered to the patient, e.g., by intravenous injection and results in a Cmax is that greater than about 2 mg/L and optionally less than about 50 mg/L.Type: ApplicationFiled: August 3, 2020Publication date: March 18, 2021Inventors: Glenn E. Dale, Sergio Lociuro, Christian Kemmer, Vincent Trebosc, Marc Gitzinger
-
Publication number: 20210077472Abstract: The invention provides antibiotic combination therapies for treating an A. baumannii infection in a subject. The combination therapies include rifabutin and a second antibiotic, such as colistin and cefiderocol.Type: ApplicationFiled: August 3, 2020Publication date: March 18, 2021Inventors: Vincent Trebosc, Christian Kemmer, Glenn E. Dale, Sergio Lociuro, Marc Gitzinger
-
Publication number: 20210077470Abstract: The invention provides formulations containing highly concentrated solutions of rifabutin and methods of making such formulations. The invention also provides methods of using such formulations to treat a bacterial infection in a subject.Type: ApplicationFiled: August 3, 2020Publication date: March 18, 2021Inventors: Sergio Lociuro, Stefano Biondi, Glenn E. Dale, Marilyne Bourotte, Marc Gitzinger
-
Patent number: 9814754Abstract: A novel combination comprising a ?-hairpin peptidomimetic of the formula cyclo(-Thr-Trp-Ile-Dab-Orn-DDab-Dab-Trp-Dab-Dab-Ala-Ser-DPro-Pro) (I), and a further compound with antibiotic activity, that enable therapeutic control of specific bacterial infections in human or animals at doses of the individual compounds lower than either of the compounds administered alone. The combination can be used as a medicament to treat e.g. skin or soft tissue infections; eye, ear, blood stream, or intra-abdominal infections; infections related to respiratory diseases, to bone diseases, to cardiovascular diseases, to genitourinal diseases, or to gastrointestinal diseases.Type: GrantFiled: August 7, 2013Date of Patent: November 14, 2017Assignee: Polyphor AGInventors: Glenn E. Dale, Daniel Obrecht, Francesca Bernardini
-
Patent number: 9775877Abstract: A novel combination comprising a ?-hairpin peptidomimetic of the formula cyclo(-Thr-Trp-Ile-Dab-Orn-DDab-Dab-Trp-Dab-Dab-Ala-Ser-DPro-Pro) (I), and a compound of the glycylcycline class, especially tigecycline, that enable therapeutic control of specific bacterial infections in human or animals at doses of the individual compounds lower than either of the compounds administered alone. The combination can be used as a medicament to treat e.g. skin or soft tissue infections; eye, ear, blood stream, or intra-abdominal infections; infections related to respiratory diseases, to bone diseases, to cardiovascular diseases, to genitourinal diseases, or to gastrointestinal diseases.Type: GrantFiled: August 7, 2013Date of Patent: October 3, 2017Assignee: POLYPHOR AGInventors: Glenn E. Dale, Daniel Obrecht, Francesca Bernardini
-
Publication number: 20150224168Abstract: A novel combination comprising a ?-hairpin peptidomimetic of the formula cyclo(-Thr-Trp-Ile-Dab-Orn-DDab-Dab-Trp-Dab-Dab-Ala-Ser-DPro-Pro) (I), and a further compound with antibiotic activity, that enable therapeutic control of specific bacterial infections in human or animals at doses of the individual compounds lower than either of the compounds administered alone. The combination can be used as a medicament to treat e.g. skin or soft tissue infections; eye, ear, blood stream, or intra-abdominal infections; infections related to respiratory diseases, to bone diseases, to cardiovascular diseases, to genitourinal diseases, or to gastrointestinal diseases.Type: ApplicationFiled: August 7, 2013Publication date: August 13, 2015Applicant: POLYPHOR AGInventors: Glenn E. Dale, Daniel Obrecht, Francesca Bernardini